文献速递神经肿瘤

小病理组织样本导致异柠檬酸脱氢酶野生型胶质瘤诊断分级偏低常见

Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
PubMed 文献 · Neurosurgery · 2019-01-01

该研究评估111例IDH野生型胶质瘤患者病理样本大小对组织学分级的影响,发现平均样本量10.9 cc者83.8%诊断为WHO IV级,平均2.62 cc者16.2%诊断为WHO II/III级,绝对样本量按WHO分级分层差异显著(P=.0374),作者建议每次切除的标准最小样本量(>5cc)。

要点

  • 小样本量与IDHwt胶质瘤组织学分级低估恶性风险相关
  • 样本量>10 cc的肿瘤100%病理诊断为WHO IV级,>5 cc者93.5%为WHO IV级
  • 作者建议每次切除的标准最小样本量(>5cc)

核心结论

  • 小样本量与IDHwt胶质瘤组织学分级中低估恶性程度的风险较高相关,本研究建议每次切除的标准最小样本量(>5cc)。

研究设计与样本

  • 评估2007年1月至2015年12月在本院接受IDHwt胶质瘤切除的111例患者的组织学诊断WHO分级、样本体积和术前肿瘤体积数据。

主要发现

  • 平均样本量10.9 cc,83.8%的患者组织学诊断为WHO IV级,而16.2%的患者平均样本量2.62 cc,诊断为WHO II/III级。
  • 单因素置换检验显示按WHO分级分层的绝对组织样本量之间差异显著(P=.0374)。
  • 术前肿瘤体积在WHO IV级与WHO II/III级之间的分布无显著差异(P=.8587)。
  • 所有样本量>10 cc的肿瘤100%病理诊断为WHO IV级,样本量>5 cc者93.5%诊断为WHO IV级。

临床怎么用

  • 作者建议每次切除的标准最小样本量(>5cc)。
  • IDHwt、WHO II/III级胶质瘤的辅助治疗方式需反映其预后仅略优于胶质母细胞瘤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In contrast to isocitrate dehydrogenase (IDH) mutation analysis, which is homogenous within a given tumor, diagnostic errors in histological analysis following the 2016 World Health Organization (WHO) classification could be due to small samples because of histological heterogeneity. OBJECTIVE: To assess whether the sample size sent to histopathology influences the tumor grading in IDH wild-type gliomas. METHODS: Histologically diagnosed WHO grade, sample volume, and preoperative tumor volume data of 111 patients aged who received resection of IDHwt gliomas between January 2007 and December 2015 at our hospital were evaluated. The differences between absolute and relative pathological sample sizes stratified by WHO grade were conducted using One-Way-Permutation-Test. RESULTS: With a mean sample size of 10.9 cc, 83.8% of patients were histologically diagnosed as WHO grade IV, while 16.2% of patients with a mean sample size of 2.62 cc were diagnosed as WHO grade II/III. One-Way-Permutation-Test showed a significant difference between absolute tissue samples stratified by WHO grade (P = .0374). The distribution of preoperative tumor volumes with WHO grade IV vs WHO grade II/III showed no significant difference (P = .8587). Of all tumors with a sample size >10 cc 100% were pathologically diagnosed as WHO grade IV and those with sample size >5 cc 93.5% were diagnosed as WHO grade IV. CONCLUSION: Small sample sizes are associated with a higher risk of under-estimating malignancy in histological grading in IDHwt gliomas. This study suggests a standard minimum sample size (>5cc) in every resection. Modalities of adjuvant treatment for IDHwt, WHO grade II/III gliomas need to reflect a prognosis that is only marginally better than of a glioblastoma.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Gutt-Will M, Murek M, Schwarz C, et al. Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples. Neurosurgery. 2019. PMID: 30335178. doi:10.1093/neuros/nyy433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。